 BOSTON, April 01, 2022 GLOBE NEWSWIRE -- Praxis Precision Medicines, Inc. NASDAQ: PRAX, a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system CNS disorders characterized by neuronal excitation-inhibition imbalance, today announced that data from its PRAX-944 essential tremor ET program will be presented at the upcoming 2022 American Academy of Neurology AAN Annual Meeting, which will take place in Seattle, Washington from April 2 7, 2022 and virtually from April 24 26, 2022. Abstracts can be accessed on the AAN meeting website. 